Default Category
-
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
Herzlinger, Regina E.; Otazo, AndrewCase HBS-315045-EEntrepreneurshipA medical device startup seeks to complete its clinical trials with very little startup funding and a small staff when compared to its competitors.Starting at €8.20
-
Duke Energy y el Renacimiento Nuclear
Vietor, Richard H.K.; Reinhardt, Forest L.Case HBS-717S05EconomicsPara maximizar su eficacia, los casos de color deben imprimirse en color. Duke Energy, una empresa eléctrica de propiedad del inversor estadounidense, se enfrenta a miles de millones de dólares de decisiones sobre su mezcla de combustible futuro. En particular, sus líderes están considerando la construcción de nueva capacidad nuclear. Si esto es razonable depende, entre otras cosas, sobre el crecimiento de la demanda, los costos de capital, los p...Starting at €8.20
-
CME Group (Spanish version)
Reinhardt, Forest L.; Weber, JamesCase HBS-718S03EconomicsEl caso describe el CME Group, bolsa de productos más grande del mundo, los futuros y opciones sobre futuros, la historia, la regulación y las decisiones estratégicas de la empresa enfrentó. CME Group se formó a partir de los intercambios más antiguas y conocidas en el mundo. Los operadores en el intercambio compran y venden contratos con el fin de cubrir el riesgo o especular sobre las tendencias de los precios futuros. En las últimas décadas el...Starting at €8.20
-
Mayo Clinic: The 2020 Initiative
Herzlinger, Regina E.; Huckman, Robert S.; Lesser, JennyCase HBS-615027-EDescribes the challenges facing Dr. John Noseworthy, President and CEO, in implementing a long-term strategy for the growth of the Mayo Clinic-a leading academic medical center with a reputation for excellence in tertiary and quaternary health care. The case highlights the concurrent forces of regional and national competition and federal health care reform as factors complicating the plans of Mayo Clinic to grow through several channels. Student...Starting at €8.20
-
McKesson
Herzlinger, Regina E.; Kindred, NatalieCase HBS-312002-EMcKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into health care services with the acquisition of U.S. Oncology, an integrated cancer care company, whose expertise it could leverage in offerings catered to other physician specialties. Wi...Starting at €8.20
-
Cancer Treatment Centers of America (A)
Herzlinger, Regina E.; Kindred, NatalieCase HBS-313012-EService and Operations ManagementCancer Treatment Centers of America (CTCA), a U.S. network of four privately owned oncology focused factory hospitals, was weighing options for growth. CTCA was entirely cancer focused and specialized in treating patients with complex and advanced-stage cancers, who were reached through advertising its integrative, team-based approach to care. CEO Stephen Bonner needed to decide whether to focus future expansion on building additional full-scale ...Starting at €8.20
-
Shanghai Pharmaceuticals
Herzlinger, Regina E.; Kindred, NatalieCase HBS-313016-EStrategyShanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company-essentially a collection of subsidiaries operating under a unified management structure-was formed through the 2009 merger of several state-owned enterprises, part of a broad policy effort in China to streamline state assets, ...Starting at €8.20
-
-
CV Ingenuity (A) and (B), Teaching Note
Herzlinger, Regina E.Teaching Note HBS-317119-ETeaching note for cases 315045 and 315087.Starting at €0.00
-
Syngenta: Committing to Africa
Reinhardt, Forest L.; Shelman, MaryCase HBS-715010-EStrategyIn 2012, Syngenta, one of the world's largest agricultural input company, committed to build a $1 billion business in Africa over the next 10 years. In mid-2014, CEO Michael Mack and Africa Venture Team head Dimitri Pauwels are reviewing progress. Was the company's committment to Africa still relevant and achievable?Starting at €8.20